Quick answer
Vascular anomalies and PIK3CA-related overgrowth spectrum (PROS) were for decades a surgical problem with poor results: resecting a malformation that permeates muscle and nerve leaves deformity and often recurs. The discovery that PIK3CA mutations drive both gave the field a drug target. Lin Xiaoxi's team at Shanghai Ninth People's Hospital has spent 30 years on these diseases and now sits at the centre of that shift — leading principal investigator for the global alpelisib trial, and sponsor-investigator of Chinese trials of a domestic PI3K-alpha inhibitor and a MEK inhibitor for arteriovenous malformation [1][2][4].
Key takeaways
- Alpelisib became the first approved targeted drug for PROS in patients aged 2 and over, following trials in which the Shanghai team was leading PI [6].
- PROS was added to China's national rare disease list in 2023 and Shanghai's list in 2025, with the team's advocacy cited [1][2].
- The team leads a phase I/II trial of CYH33, a domestic highly selective PI3K-alpha inhibitor, and completed the first Chinese adolescent dosing (12–18 years) in October 2024 [2].
- A CDE-approved multicentre trial of the MEK inhibitor FCN-159 for adult extracranial AVM was published in Clinical Cancer Research [1].
- The team published 16 PROS-related papers in three years, including a facial infiltrating lipomatosis mechanism study in Advanced Science [3][4].
Why a genetic diagnosis changes the treatment
PROS comprises Klippel-Trenaunay syndrome, CLOVES and facial infiltrating lipomatosis, all caused by somatic mosaic PIK3CA mutations. Because the mutation is present only in affected tissue, blood tests miss it and diagnosis depends on biopsying the lesion. Once known, however, it converts an anatomical problem into a molecular one: the PI3K-alpha pathway is constitutively active, and inhibiting it shrinks the overgrowth [2][6].
The same logic extends to arteriovenous malformation, where MAP2K1 and related mutations activate the MEK pathway. The FCN-159 trial is described as the first strictly prospective clinical study of targeted therapy in adult extracranial AVM, and the team also published methodology in the New England Journal of Medicine on how to define trial endpoints in this disease — a problem that had blocked the field, because AVM volume is hard to measure reproducibly [1].
What targeted therapy does and does not do
Alpelisib shrinks lesions, reduces pain and bleeding, and improves function in PROS. It does not cure: the mutation remains, and stopping the drug is generally followed by regrowth, so treatment is long-term with the attendant metabolic toxicity of PI3K inhibition — hyperglycaemia, stomatitis, rash [6].
PROS is rare, so trials are small and single-arm; the evidence for survival or function comes from open-label cohorts. A domestic PI3K-alpha inhibitor matters mainly because it could make lifelong therapy affordable in China, where the imported drug is costly and not universally reimbursed. The adolescent dosing milestone is a phase I/II result in a handful of patients, not proof of comparable efficacy [2][5]. Surgery and interventional radiology remain necessary alongside drug therapy [4].
The condition in context: vascular anomalies
These diseases are frequently misdiagnosed as cosmetic, and their burden is functional as well as psychological.
| Region | What the data shows | Source |
|---|---|---|
| Presentation | Lesions grow during childhood and rapidly at puberty, causing deformity, pain and bleeding [5]. | Ninth People's Hospital [5] |
| Genetic basis | PROS is caused by somatic mosaic PIK3CA mutations; about 30% have macrocephaly or scoliosis [6]. | Baidu Baike [6] |
| Recognition | PROS joined China's national rare disease list in 2023 [1][2]. | The Paper [1][2] |
Because local treatment cannot control widespread lesions, systemic targeted therapy is the only approach that addresses the whole disease [5].
Why it matters
| Potential | What the report suggests | Source |
|---|---|---|
| Drug access | Domestic PI3K-alpha inhibitor in trials could reduce cost [2]. | [2] |
| Methodology | Published endpoint standards for AVM trials [1]. | [1] |
| Caution | Small open-label trials; drug is suppressive, not curative [6]. | [6] |
Availability and limits
- This is an editorial summary of hospital and conference reporting, not a treatment recommendation [1][2].
- CYH33 and FCN-159 remain investigational [1][2].
- Alpelisib requires long-term therapy with metabolic monitoring [6].
- Genetic testing of lesional tissue is needed for diagnosis [2].
- Surgery and embolisation remain part of care [4].
What to ask before booking
| Question | Why it matters |
|---|---|
| Has the lesion been sequenced for PIK3CA or MAP2K1? | The drug choice depends on the driver mutation [2]. |
| Are any trials enrolling, and at what age? | The AVM trial has widened from 18–65 to 12–70 years [5]. |
| Which department handles foreign patients, and in what language? | The hospital is a working hospital we do not book; confirm international-department coordination and language support. |
| What monitoring does long-term PI3K inhibition require? | Hyperglycaemia and mucosal toxicity are common [6]. |
Questions patients ask
What has the team achieved?
Leading PI role in the global alpelisib PROS trial, sponsorship of a domestic PI3K-alpha inhibitor trial (CYH33) including first adolescent dosing, and a CDE-approved MEK inhibitor trial (FCN-159) in extracranial AVM [1][2].
Is targeted therapy curative?
No — it shrinks lesions and improves symptoms, but regrowth follows withdrawal, so therapy is long-term [6].
Why does a domestic drug matter?
Lifelong therapy with an imported drug is expensive; a domestic alternative could widen access [2].
Is this relevant to international patients?
It is useful context for China's rare disease programmes. The hospital is a working hospital we do not book — contact its international department directly [1].
What is PROS?
PIK3CA-related overgrowth spectrum — Klippel-Trenaunay syndrome, CLOVES and facial infiltrating lipomatosis, caused by somatic mosaic PIK3CA mutations [6].